Phase II study of docetaxel and oxaliplatin in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer (NSCLC).
2010 ◽
Vol 28
(15_suppl)
◽
pp. e18022-e18022
Keyword(s):
Phase Ii
◽